journal article·2023-07

A supramolecular assembly strategy for hydrophilic drug delivery towards synergistic cancer treatment

Haijing Qu, Han Chen, Wei Cheng, Yanjun Wang, Yangyang Xia, Linghao Zhang, Buyong Ma, Rong Hu, Xiangdong Xue

Acta Biomaterialia· Volume 164
Publisher page

Abstract

To improve the drug loading, tumor targeting, and delivery simplicity of hydrophilic drugs, we propose a supramolecular assembly strategy that potentially benefits a wide range of hydrophilic drug delivery. Firstly, we choose a hydrophilic drug (tirapazamine) as a model drug to directly co-assemble with chlorin e6 (Ce6) at different molar ratios, and systematically evaluate the resultant Ce6-tirapazamine nanoparticles (CT NPs) in aspects of size distribution, polydispersity, morphology, optical properties and molecular dynamics simulation. Based on the assembling facts between Ce6 and tirapazamine, we summarize a plausible rule of the supramolecular assembly for hydrophilic drugs. To validate our findings, more drugs with increasing hydrophilicity, such as temozolomide, gemcitabine hydrochloride and 5-azacytidine, successfully co-assemble with Ce6 into nanostructures by following similar assembling behaviors, demonstrating that our assembling rule may guide a wide range of hydrophilic drug delivery. Next, the combination of Ce6 and tirapazamine was chosen as the representative to investigate the anti-tumor activities of the supramolecular assemblies. CT NPs showed synergistic anti-tumor efficacy, increased tumor accumulation and significant tumor progression and metastasis inhibition in tumor-bearing mice. We anticipate that the supramolecular assembly mechanism will provide broad guidance for developing easy-to-make but functional nanomedicines. STATEMENT OF SIGNIFICANCE: Although thousands of nanomedicines have been developed, only a few have been approved for clinical use. The manufacturing complexity significantly hinders the "bench-to-bed" translation of nanomedicines. Hence, we need to rethink how to conduct research on translational nanomedicines by avoiding more and more complex chemistry and complicated nanostructures. Here, we summarize a plausible rule according to multiple supramolecular assembly pairs and propose a supramolecular assembly strategy that can improve the drug loading, tumor targeting, and manufacturing simplicity of nanomedicine for hydrophilic drugs. The supramolecular assembly strategy would guide a broader range of drug delivery to provide a new paradigm for developing easy-to-make but multifunctional nanoformulations for synergistic cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Supramolecular Self-Assembly in Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (42)

Show source-provided references
1. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
2. Brain co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy10.1002/adma.202203958 ↗
3. Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics10.7150/thno.38069 ↗
4. Stimuli-responsive crosslinked nanomedicine for cancer treatment10.1002/EXP.20210134 ↗
5. Novel redox-responsive polymeric magnetosomes with tunable magnetic resonance property for in vivo drug release visualization and dual-modal cancer therapy10.1002/adfm.201802159 ↗
6. Stimuli-responsive nanocarriers for drug delivery10.1038/nmat3776 ↗
7. Two-way magnetic resonance tuning and enhanced subtraction imaging for non-invasive and quantitative biological imaging10.1038/s41565-020-0678-5 ↗
8. Brain co-delivery of first-line chemotherapy drug and epigenetic bromodomain inhibitor for multidimensional enhanced synergistic glioblastoma therapy
9. A biomimetic nanomedicine targets orthotopic glioblastoma by combinatorial co-delivery of temozolomide and a methylguanine-DNA methyltransferase inhibitor
10. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
11. Indocyanine green potentiated paclitaxel nanoprodrugs for imaging and chemotherapy10.1002/EXP.20220008 ↗
12. Rational design of nanoparticles with deep tumor penetration for effective treatment of tumor metastasis10.1002/adfm.201801840 ↗
13. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond10.1016/j.jconrel.2012.04.038 ↗
14. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
15. The entry of nanoparticles into solid tumours10.1038/s41563-019-0566-2 ↗
16. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy10.1016/j.biomaterials.2013.07.037 ↗
17. Liposome composition in drug delivery design, synthesis, characterization, and clinical application10.1016/j.addr.2021.113851 ↗
18. Recent advancements in liposome technology10.1016/j.addr.2020.06.022 ↗
19. Recent advances on small-molecule nanomedicines for cancer treatment10.1002/wnan.1607 ↗
20. Tailor-made dual ph-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery10.1021/ja207150n ↗
21. Carrier-free, chemophotodynamic dual nanodrugs via self-assembly for synergistic antitumor therapy10.1021/acsami.6b02416 ↗
22. Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug-drug conjugate for cancer therapy10.1021/ja505212y ↗
23. Self-assembled nanoparticle-mediated chemophototherapy reverses the drug resistance of bladder cancers through dual AKT/ERK inhibition
24. Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment10.1038/s41467-018-06093-5 ↗
25. Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy10.1016/j.biomaterials.2018.01.044 ↗
26. Co-delivery of Bee Venom melittin and a photosensitizer with an organic-inorganic hybrid nanocarrier for photodynamic therapy and immunotherapy10.1021/acsnano.9b04181 ↗
27. Spatiotemporal drug release visualized through a drug delivery system with tunable aggregation-induced emission10.1002/adma.201302365 ↗
28. Porphyrin-based nanomedicines for cancer treatment10.1021/acs.bioconjchem.9b00231 ↗
29. Quantitative self-assembly prediction yields targeted nanomedicines10.1038/s41563-017-0007-z ↗
30. Computationally guided high-throughput design of self-assembling drug nanoparticles10.1038/s41565-021-00870-y ↗
31. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles10.1016/j.biomaterials.2011.05.007 ↗
32. PEG-functionalized iron oxide nanoclusters loaded with chlorin e6 for targeted, NIR light induced, photodynamic therapy10.1016/j.biomaterials.2013.08.041 ↗
33. Conjugation of porphyrin to nanohybrid cerasomes for photodynamic diagnosis and therapy of cancer10.1002/anie.201103557 ↗
34. Light-triggered in situ gelation to enable robust photodynamic-immunotherapy by repeated stimulations10.1002/adma.201900927 ↗
35. Near-infrared-triggered photodynamic therapy with multitasking upconversion nanoparticles in combination with checkpoint blockade for immunotherapy of colorectal cancer10.1021/acsnano.7b00715 ↗
36. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗
37. Combinational phototherapy and hypoxia-activated chemotherapy favoring antitumor immune responses10.2147/IJN.S203383 ↗
38. Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma10.1023/A:1008249232000 ↗
39. Tirapazamine: A hypoxia-activated topoisomerase II poison
40. Selectively potentiating hypoxia levels by combretastatin A4 nanomedicine: toward highly enhanced hypoxia-activated prodrug tirapazamine therapy for metastatic tumors10.1002/adma.201805955 ↗
41. Engineering bioluminescent bacteria to boost photodynamic therapy and systemic anti-tumor immunity for synergistic cancer treatment10.1016/j.biomaterials.2021.121332 ↗
42. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy10.1038/ncomms13193 ↗